Alethio Therapeutics logo featuring a blue and purple geometric symbol alongside the biotechnology company's name.
UK-based Alethio Therapeutics secured $90 million in Series A financing to support clinical development of ATX-011 for essential thrombocythaemia and advance additional blood cancer treatment programmes.

Alethio Therapeutics, a UK-based biopharmaceutical company developing targeted treatments for chronic blood cancers, has raised $90 million (£67 million) in an oversubscribed Series A funding round co-led by Sofinnova Partners and RA Capital.

The financing also included founding investor Oxford Science Enterprises, with participation from Cancer Research Horizons and the University of Oxford.

Founded in 2021 by Professors Adam Mead and Beth Psaila as a University of Oxford spinout, Alethio Therapeutics focuses on developing disease-modifying therapies for myeloproliferative neoplasms (MPNs), a group of blood cancers characterised by abnormal blood cell production. The company is led by CEO Dr Rohit Batta.

Alethio’s lead programme, ATX-011, is an investigational monoclonal antibody targeting G6B, a protein found on platelets, megakaryocytes and certain disease-driving cells. The treatment is being developed for essential thrombocythaemia (ET), a blood cancer associated with excessive platelet production and increased risks of blood clots and other complications.

The company aims to use ATX-011 to reduce abnormal platelet counts and address underlying disease mechanisms rather than solely managing symptoms. The programme remains in preclinical development, with studies underway to support future clinical testing.

Alethio plans to use the new funding to advance ATX-011 through Phase 1/2a clinical studies in ET and towards Phase 3 readiness. Part of the capital will also support additional MPN treatment programmes as they progress towards Investigational New Drug (IND) submissions.

The company’s drug discovery work is supported by its ARTEMIS platform, which combines patient-derived biological data, advanced molecular analysis, machine learning and disease-relevant models to identify potential therapeutic targets.

Preclinical research involving ATX-011 has also been selected for an oral presentation at the American Society of Hematology (ASH) 2026 Annual Meeting.

Following the financing, Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Maxwell DeNies of RA Capital have joined Alethio’s board of directors.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share